Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells. (Q39617351)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

0 references

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Laure Marignol

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

James C Forde

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Kevin Brennan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Lynn M Martin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Mark P Lawler

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Thomas H Lynch

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Donal Hollywood

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

21 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

912-919

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluoresce

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Hypoxia in prostate cancer: a powerful shield against tumour destruction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Hypoxia and drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Involvement of MGr1-Ag/37LRP in the vincristine-induced HIF-1 expression in gastric cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Taxane refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Molecular mechanisms of patupilone resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Clinical pharmacokinetics of docetaxel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

How do microtubule-targeted drugs work? An overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Microtubule dynamics as a target in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Microtubules as a target for anticancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

Docetaxel: a review of its use in metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.015

10.1016/J.UROLONC.2010.08.015

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176881%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference